Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311268 | PMC |
| http://dx.doi.org/10.1016/j.jaccas.2021.03.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Three-Year Outcomes With a Supra-Annular, Self-Expanding Bioprosthesis and a Pericardial Wrap-The FORWARD PRO Study.
Catheter Cardiovasc Interv
December 2024
Center of Innovative Interventions in Cardiology, University Hospital Bonn, Bonn, Germany.
Background: The self-expanding, supra-annular Evolut valve is an established platform for Transcatheter Aortic Valve Implantation (TAVI). Evolut PRO introduced an outer sealing wrap to mitigate paravalvular leakage. We evaluated the 3-year clinical outcomes and valve performance of the Evolut PRO in standard clinical practice for severe aortic stenosis (AS) patients at intermediate or higher risk for surgery.
View Article and Find Full Text PDFManagement of Surgical Transcatheter Aortic Valve Replacement (TAVR) Valve Explantation for Early Degeneration: A Case Report.
Cureus
October 2024
Cardiothoracic Surgery, Albany Medical Center, Albany, USA.
Early degeneration of the bioprosthetic aortic valve after transcatheter aortic valve replacement (TAVR) requires aortic valve reintervention, especially in young patients. However, the management of aortic valve reintervention after TAVR is not established. In this case report, the authors report a young patient with an early degenerated TAVR valve who underwent TAVR valve explantation and surgical aortic valve replacement with a mechanical valve.
View Article and Find Full Text PDFImportance: Guidelines advise heart team assessment for all patients with aortic stenosis, with surgical aortic valve replacement recommended for patients younger than 65 years or with a life expectancy greater than 20 years. If bioprosthetic valves are selected, repeat procedures may be needed given limited durability of tissue valves; however, younger patients with aortic stenosis may have major comorbidities that can limit life expectancy, impacting decision-making.
Objective: To characterize patients younger than 65 years who received transcatheter aortic valve replacement (TAVR) and compare their outcomes with patients aged 65 to 80 years.
Initial Findings Concerning the Latest Self-Expandable Evolut FX Valve: A Report Using OCEAN-TAVI Registry Data.
Am J Cardiol
January 2025
Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Data concerning the clinical effect of the latest-generation self-expandable transcatheter heart valve (Evolut FX) remain limited. We aimed to assess the in-hospital outcomes of 3 bioprosthetic valves (Evolut EPO, PRO+, and FX). We analyzed data from a Japanese multicenter registry involving 634 consecutive patients who underwent transcatheter aortic valve replacement with Evolut FX up until October 2023.
View Article and Find Full Text PDFThree-Year Outcomes Following TAVR in Younger (<75 Years) Low-Surgical-Risk Severe Aortic Stenosis Patients.
Circ Cardiovasc Interv
November 2024
Department of Interventional Cardiology and Cardiothoracic Surgery, Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, TX (N.S.K., M.J.R.).
Article Synopsis
- A study compared transcatheter aortic valve replacement (TAVR) with traditional surgery in low-risk patients under 75 years old with severe aortic stenosis to evaluate safety and effectiveness over three years.* -
- Results showed that TAVR patients had similar overall mortality rates but significantly fewer disabling strokes (0.6%) compared to surgery patients (2.9%), while TAVR also resulted in better valve performance.* -
- Both treatment options had comparable low rates of valve reinterventions, but TAVR patients experienced higher rates of pacemaker implantation (21.0% vs. 7.1%).*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!